A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya
Natura: Artigo
Lingua:inglese
Pubblicazione: 2025
Accesso online:https://doi.org/10.1183/13993003.02231-2024
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Lascia un commento!
Entra

Documenti analoghi